Iron Homeostasis in Neurodegeneration

Iron Homeostasis in Neurodegeneration

Overview

Iron Homeostasis In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

Iron homeostasis is critical for normal brain function, as iron is an essential cofactor for oxidative phosphorylation, neurotransmitter synthesis, and myelin production. However, dysregulated iron metabolism is a hallmark feature of multiple neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Iron accumulation in specific brain regions correlates with disease progression and severity, making iron homeostasis a key therapeutic target. [@weinreb2007]

Iron Metabolism Overview

Systemic Iron Regulation

Iron balance in the body is tightly controlled through hepcidin-mediated regulation: [@ward2014]

```mermaid
flowchart TD
subgraph Systemic_Iron
A["Intestinal Iron<br/>Absorption"] --> B["Transferrin"]
B --> C["Non-transferrin-bound<br/>Iron NTBI"]
C --> D["Ferritin<br/>Storage -> "]
D --> E["Brain Iron<br/>Entry"]
end

subgraph Brain_Iron
E --> F["Divalent Metal<br/>Transporter 1 DMT1"]
F --> G["Neurons"]
F --> H["Oligodendrocytes"]
F --> I["Microglia"]
end

J["Hepcidin"] -.->|"Regulates"| A
J -.->|"Regulates"| F

Iron Homeostasis in Neurodegeneration

Overview

Iron Homeostasis In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

Iron homeostasis is critical for normal brain function, as iron is an essential cofactor for oxidative phosphorylation, neurotransmitter synthesis, and myelin production. However, dysregulated iron metabolism is a hallmark feature of multiple neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Iron accumulation in specific brain regions correlates with disease progression and severity, making iron homeostasis a key therapeutic target. [@weinreb2007]

Iron Metabolism Overview

Systemic Iron Regulation

Iron balance in the body is tightly controlled through hepcidin-mediated regulation: [@ward2014]

Key Proteins in Brain Iron Metabolism

| Protein | Function | Brain Expression | [@muckenthaler2017]
|---------|----------|------------------| [@belaidi2016]
| Transferrin (TF) | Iron transport in blood and CSF | Produced in choroid plexus |
| Ferritin (FTL/FTH) | Iron storage | All neural cell types |
| DMT1 | Ferrous iron transporter | Neurons, oligodendrocytes |
| Ferroportin (FPN) | Iron export | Neurons, microglia, endothelial cells |
| Hepcidin (HAMP) | Systemic iron regulation | Limited brain expression |
| IRP/IRE system | Post-transcriptional iron regulation | Ubiquitous |

Iron in Parkinson's Disease

Substantia Nigra Iron Accumulation

Parkinson's disease is characterized by dramatic iron accumulation in the substantia nigra pars compacta (SNpc), particularly in neuromelanin-containing dopaminergic neurons:

• Iron levels in SNpc are 2-3 times higher in PD patients compared to age-matched controls
• Iron accumulation correlates with loss of dopaminergic neurons
• Ferritin expression is increased in microglia surrounding degenerating neurons

Molecular Mechanisms

Iron-Dopamine Interaction

Dopaminergic neurons are particularly vulnerable to iron toxicity due to:

Iron in Alzheimer's Disease

Regional Iron Distribution

Iron accumulates in brain regions affected by AD pathology:

• Hippocampus: Iron co-localizes with amyloid plaques and neurofibrillary tangles
• Cortex: Iron in neurons and microglia, associated with amyloid deposits
• Choroid plexus: Dysregulated iron transport across BBB

Iron and Amyloid Interaction

Ferroptosis in AD

[Ferroptosis](/entities/ferroptosis), an iron-dependent form of non-apoptotic cell death, contributes to neuronal loss in AD:

• GPX4 downregulation: Reduced glutathione peroxidase 4 activity
• Lipid peroxidation: Iron-catalyzed oxidation of polyunsaturated fatty acids
• System Xc⁻ dysfunction: Cystine/glutamate antiporter impairment

Iron in Other Neurodegenerative Diseases

Huntington's Disease

• Iron accumulation in striatum and [cortex](/brain-regions/cortex)
• Mutant [huntingtin](/proteins/huntingtin) impairs iron regulatory protein function
• Increased DMT1 expression in vulnerable regions

Amyotrophic Lateral Sclerosis

• Iron accumulation in motor [neurons](/entities/neurons) and spinal cord
• Dysregulated ferritin expression in [astrocytes](/entities/astrocytes)
• Iron-responsive element binding protein alterations

Multiple System Atrophy

• Iron accumulation in olivary nuclei and basal ganglia
• Co-localization with oligodendroglial cytoplasmic inclusions

Therapeutic Strategies

Iron Chelation Therapy

| Agent | Mechanism | Clinical Status |
|-------|-----------|-----------------|
| Deferoxamine (DFO) | Binds Fe³⁺ systemically | Phase II trial (PD); mixed results |
| Deferasirox (DFX) | Oral iron chelator | Preclinical |
| Clioquinol | Cu/Zn chelator with effects on Fe | Phase II (AD) - slowed cognitive decline |
| PBT2 | Metal-protein attenuation | Phase II (AD, HD) - failed primary endpoints |

Iron Import Inhibition

• DMT1 inhibitors: Block excessive iron entry into neurons
• Ferroportin activators: Enhance iron export

Neuroprotective Approaches

• Ferroptosis inhibitors: Liproxstatin-1, vitamin E
• Antioxidants: CoQ10, N-acetylcysteine
• Iron-sulfur cluster donors: Restore mitochondrial function

Biomarkers

Imaging Biomarkers

• MRI (R2*): Quantitative susceptibility mapping for brain iron
• Transcranial Sonography: Hyperechogenicity of substantia nigra

Blood Biomarkers

• Serum ferritin: Elevated in PD progression
• Transferrin saturation: Altered in neurodegenerative diseases
• Hepcidin levels: Dysregulated in AD and PD

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Ferroptosis](/mechanisms/ferroptosis)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Alpha-Synuclein](/mechanisms/alpha-synuclein)
• [DMT1](/genes/dmt1)
• [Ferroportin](/entities/ferroportin)
• [Ferritin](/entities/ferritin)

Background

The study of Iron Homeostasis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

Recent publications advancing our understanding of this mechanism:

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

External Links

• [KEGG: Iron homeostasis](https://www.kegg.jp/pathway/hsa01040)
• [Iron Disorders Institute](https://irondisorders.org/)
• [Michael J. Fox Foundation - Iron Dysregulation in PD](https://www.michaeljfox.org/)